2015 ANTIMICROBIAL OVERVIEW -...
Transcript of 2015 ANTIMICROBIAL OVERVIEW -...
1
Antimicrobial Overview June 2015
Rutgers, The State University of New Jersey
Laureen A. Klein, Pharm.D.
PANCE/PANRE Review Course
General Principles
• Narrowest spectrum possible to avoid resistance
• Wider spectrum (including multiple agents) – neutropenic fever, polymicrobial infection, synergism (two agents with different mechanisms of action), tuberculosis
• Ensure compliance
PANCE/PANRE Review Course
Aerobic Gram-Positive Bacteria
• Streptococcus
• Staphylococcus
• Enterococcus
• Cornybacterium
• ListeriaListeria
2
PANCE/PANRE Review Course
Aerobic Gram-Negative Bacteria
• Enterobacteriaceae (E. coli, Klebsiella, Enterobacter, Citrobacter, Proteus, Serratia, Salmonella, Shigella, Morganella, Providencia)
• Pseudomonas• Helicobacter• Haemophilus• Haemophilus• Legionella• Moraxella• Neisseria
PANCE/PANRE Review Course
Anaerobic Bacteria
• Gram-Positive• Peptococcus
• Peptostreptococcus
• Clostridia
• Propionibacterium acnes
• Gram-Negative• Bacteroides
• Fusobacterium
• Propionibacterium acnes
PANCE/PANRE Review Course
Atypicals
• Chlamydia
• Chlamydophila
• Rickettsiae
• Mycoplasma
• Spirochetes (Syphilis, Lyme disease)Spirochetes (Syphilis, Lyme disease)
• Mycobacterium (tuberculosis, mycobacterium avium complex [MAC])
3
PANCE/PANRE Review Course
Mechanisms of Action (MOA)
• Cell wall synthesis inhibitors – beta-lactams (penicillins, cephalosporins, monobactam, carbapenems), vancomycin, lipoglycopeptides, fosfomycin, bacitracin
• Protein synthesis inhibitors – macrolides, ketolides, aminoglycosides tetracyclines metronidazoleaminoglycosides, tetracyclines, metronidazole, dalfopristin/quinupristin, oxazolidinones (linezolid, tedizolid), clindamycin
• Inhibition of enzymes – rifampin (RNA polymerase), fluoroquinolones (topoisomerase), sulfamethoxazole/ trimethoprim (folic acid)
PANCE/PANRE Review Course
Penicillins
• MOA: beta-lactams; bind to penicillin binding protein to inhibit cell wall synthesis
• Spectrum: gram-positives (S. pneumoniae & Staphylococcal resistance), gram-negatives, anaerobes
• Most eliminated renally
• Resistance: beta-lactamase, altered penicillin binding protein, altered penetration
• AEs: hypersensitivity, GI, hematological, seizures, interstitial nephritis
PANCE/PANRE Review Course
Natural Penicillins(Pen G, Pen VK [PO], Procaine [IM], Benzathine IM])
• Spectrum: Treponema pallidum, Streptococcal species (pyogenes, pneumoniae [resistance]), Enterococcus (combined with aminoglycoside), Neisseria meningitidis, Borrelia burgdorferi, anaerobes above diaphragm
• Indications: syphilis and strep respiratory tract infections including S. pneumoniae and S. pyogenes
4
PANCE/PANRE Review Course
Antistaphylococcal Penicillins(dicloxacillin, nafcillin, oxacillin, methicillin)
• Spectrum: staphylococcal and streptococcal infections only
• Effective for penicillinase producing organisms• If methicillin resistantresistant to all beta lactams• If methicillin resistant resistant to all beta-lactams
except ceftaroline• Indications: sensitive staphylococcal infections, generally
skin infections• Nafcillin has hepatobiliary elimination
PANCE/PANRE Review Course
Amino Penicillins (ampicillin, amoxicillin)
• Spectrum: Streptococcal species, Enterococci, Listeria, Enterobacteriaceae, Borrelia burgdorferi, Helicobacter pylori
• Indications: respiratory tract infections, Lyme, GI ulcers – H. pylori, endocarditis prophylaxis
• Mononucleosis – maculopapular rash – no urticaria
PANCE/PANRE Review Course
Extended-Spectrum Penicillins(piperacillin, ticarcillin)
• Spectrum: extended gram-negative coverage including Pseudomonas aeruginosa
• Indications: infections in hospitalized patients
• Intravenous only – inpatient treatment y p
5
PANCE/PANRE Review Course
Penicillin + Beta-lactamase Inhibitors
• Agents: oral - amoxicillin/clavulanate (Augmentin), IV -ampicillin/sulbactam (Unasyn), piperacillin/tazobactam (Zosyn), ticarcillin/clavulanate (Timentin)
• Spectrum: extends spectrum to beta-lactamase producing organisms (eg, S. aureus, Haemophilus, Neisseria, Moraxella, Bacteroides, Enterobacteriaceae))
• Indications: Augmentin - respiratory tract infections, animal bites, skin infections and Others - serious infections
• AE: clavulanatediarrhea
PANCE/PANRE Review Course
Cephalosporins
• MOA: beta-lactams, inhibit cell wall synthesis
• Spectrum: gram-positive, gram-negative
• 1st, 2nd, 3rd, 4th, 5th generation
• Mostly renal elimination
• AEs: hypersensitivity (cross-sensitivity with penicillin), GI,AEs: hypersensitivity (cross sensitivity with penicillin), GI, hematologic, serum sickness
• Drug interactions: some have decreased absorption with decreased GI acidity
PANCE/PANRE Review Course
First Generation Cephalosporins
• Oral: cephalexin (Keflex), cephradine (Velosef), cefadroxil (Duricef)
• Parenteral: cefazolin (Ancef, Kefzol)• Spectrum: gram-positives (staph and strep), limited gram-
negatives, oral anaerobes• Indications: alternative for staphylococcal (MSSA) and• Indications: alternative for staphylococcal (MSSA) and
streptococcal infections, surgical prophylaxis
6
PANCE/PANRE Review Course
Second Generation Cephalosporins
• Oral: cefaclor (Ceclor), cefprozil (Cefzil), cefuroxime (Ceftin)
• Parenteral: cefuroxime (Zinacef), cefoxitin (Mefoxin), cefotetan (Cefotan)
• Spectrum: MSSA, S pneumoniae, S pyogenes, H influenzae, Proteus, Moraxella catarrhalis, Borrelia burgorferi – less gram-positive and more gram-negative than first generation
– anaerobes – some cover B. fragilus (cefoxitin, cefotetan)
• Indications: respiratory tract infections, UTIs, Lyme, skin infections, surgical prophylaxis
PANCE/PANRE Review Course
Second Generation Cephalosporins
• Cefaclor – serum sickness
• Methylthiotetrazole (MTT) side chain – cefotetan -hypothrombinaemia, alcohol intolerance (flushing, tachycardia, N/V, hypotension, dyspnea)
PANCE/PANRE Review Course
Third Generation Cephalosporins
• Oral: cefixime (Suprax), cefpodoxime (Vantin), cefdinir (Omnicef), ceftibuten (Cedax), cefditoren (Spectracef)
• Parenteral: ceftriaxone – IV and IM (Rocephin), ceftazidime (Fortaz or Tazicef), cefotaxime (Claforan)
• Spectrum: less gram-positive and more gram-negative (H influenzae, E coli, Moraxella catarrhalis, Proteus, Klebsiella) than first and second generation, ceftriaxone – Borrelia burgdorferi– P. aeruginosa: ceftazidime
• Indications: respiratory tract infections, UTIs, meningitis (ceftriaxone, cefotaxime), gonorrhea (ceftriaxone + azithromycin or doxycycline)
• Ceftriaxone has hepatobiliary elimination
7
PANCE/PANRE Review Course
Fourth/Fifth Generation Cephalosporins
• Cefepime (Maxepime) – parenteral
– gram-positive and gram-negative activity
– increased stability to beta-lactamases and activity against Pseudomonas aeruginosa
• Ceftaroline (Teflaro)- parenteral
– gram-positive and gram-negative activity
– activity against MRSA and resistant S. pneumoniae
– no activity against Pseudomonas aeruginosa or extended spectrum beta-lactamases
PANCE/PANRE Review Course
Cephalosporin + Beta-lactamase Inhibitors
• Agents: ceftazidime and avibactam (Avycaz), ceftolozane + tazobactam (Zerbaxa)
• Spectrum = ceftazidime gram-negative coverage + coverage for beta-lactamase producing organisms – includes Pseudomonas aeruginosa
• Indications: Complicated intra-abdominal infections and urinary tract infections
• AEs: GI effects
PANCE/PANRE Review Course
Third Generation Cephalosporins
• Oral: cefixime (Suprax), cefpodoxime (Vantin), cefdinir (Omnicef), ceftibuten (Cedax), cefditoren (Spectracef)
• Parenteral: ceftriaxone – IV and IM (Rocephin), ceftazidime (Fortaz or Tazicef), cefotaxime (Claforan)
• Spectrum: less gram-positive and more gram-negative (H influenzae, E coli, Moraxella catarrhalis, Proteus, Klebsiella) than first and second generation, ceftriaxone – Borrelia burgdorferi– P. aeruginosa: ceftazidime
• Indications: respiratory tract infections, UTIs, meningitis (ceftriaxone, cefotaxime), gonorrhea (ceftriaxone + azithromycin or doxycycline)
• Ceftriaxone has hepatobiliary elimination
8
PANCE/PANRE Review Course
Monobactam
• Aztreonam (Azactam)– parenteral
• MOA: inhibits cell wall synthesis
• Spectrum: aerobic gram-negative only including Pseudomonas aeruginosa
• Indications: alternative agentg
• AEs: limited risk of cross-reactivity, GI
PANCE/PANRE Review Course
Carbapenems
• Agents: imipenem (Primaxin), meropenem (Merrem), ertapenem (Invanz), doripenem (Doribax) – all parenteral
• MOA: inhibits cell wall synthesis• Spectrum: very broad, includes gram-positives, gram-
negatives, anaerobes– Ertapenem has narrower spectrum – no Pseudomonas– Ertapenem has narrower spectrum – no Pseudomonas– Coverage includes extended spectrum beta-lactamase (ESBL)
producing organisms
• AEs: hypersensitivity (cross-reactivity with penicillins), GI, seizures, hypotension
PANCE/PANRE Review Course
Fluoroquinolones
• norfloxacin (Noroxin)
• ciprofloxacin (Cipro)
• ofloxacin (Floxin)
• levofloxacin (Levaquin)
• gemifloxacin (Factive)gemifloxacin (Factive)
• moxifloxacin (Avelox)
*Oral and parenteral agents
*Renal and hepatic elimination
9
PANCE/PANRE Review Course
Fluoroquinolones
• MOA: bind to and inhibit topoisomerases II & IV
• Good tissue penetration
• Spectrum: gram-positives (issues of resistance), gram-negatives (cipro & levo - P. aeruginosa, gonorrhea resistance), atypicals (chlamydia, mycoplasma), some have ), yp ( y , y p ),anaerobic coverage – moxifloxacin
• Resistance: modified DNA gyrase
• Concentration-dependent efficacy and post-antibiotic effect
• Indications: respiratory tract infections, skin infections (newer agents), UTIs, anthrax, GI infections (Salmonella, Shigella, Traveler’s diarrhea)
PANCE/PANRE Review Course
Fluoroquinolones - Adverse Events
• GI
• CNS – headache, peripheral neuropathy
• Cartilage toxicity (no peds)
• Tendinitis and tendon rupture – black box warning
Ph t iti it• Photosensitivity
• QT prolongation
• Hypo/hyperglycemia
• Rash
• Exacerbation of myasthenia gravis
• Increased liver function tests
PANCE/PANRE Review Course
Fluoroquinolones - Drug Interactions
• Divalent/trivalent cations - chelation
• Drugs affecting QT interval
• Drugs affecting blood glucose
• Theophylline
• WarfarinWarfarin
10
PANCE/PANRE Review Course
Macrolides• Agents: erythromycin, clarithromycin (Biaxin), azithromycin
(Zithromax)
• oral/parenteral
• MOA: inhibit protein synthesis
• Spectrum: – gram-positives, including Staphylococcus aureus, S pneumonia, g p , g p y , p ,
and S pyogenes, C&E>A, some staphylococcal and pneumococcal resistance
– some gram-negatives including H. pylori, H influenzae, Moraxella catarrhalis, Legionella, A>C>E, none have activity against Pseudomonas or Enterobacteriaceae)
– atypicals (mycoplasma, Chlamydophila pneumonia, Chlamydia trachomatis, Treponema pallidum)
• Indications: respiratory tract infections (CAP), GI ulcers (clarithro), MAC (azithro & clarithro), chlamydia STDs, skin infections
PANCE/PANRE Review Course
Macrolides
• Azithromycin half-life = 2-4 days
• Hepatic elimination
• AEs: GI (stimulates GI motility), ototoxicity, prolong QT, cholestatic jaundice (erythro), metallic taste (clarithromycin), phlebitis (erythro)
• Drug Interactions: inhibit cytochrome P450
PANCE/PANRE Review Course
Ketolides (telithromycin - Ketek)
• MOA: protein synthesis inhibitor• Spectrum: gram-positive, gram-negatives, atypicals, some
anaerobes• AEs: hepatic dysfunction (contraindicated in peds),
contraindicated in patients with myastenia gravis, GI, vision problems, QT prolongationproblems, QT prolongation
• Drug Interactions: inhibits cytochrome P450
11
PANCE/PANRE Review Course
Tetracyclines(tetracycline, doxycycline, minocycline)
• MOA: protein synthesis inhibitors• Spectrum: Propionibacterium acnes, H. pylori, Rickettsia,
Chlamydia, Mycoplasma, Borrelia burfdorferi, Treponema pallidum, community-acquired MRSA, Streptococcus pneumoniae (resistance issues)pneumoniae (resistance issues)
• Indications: acne, respiratory tract infections (including community-acquired pneumonia), Lyme, GI ulcers (tetracycline), Rocky Mountain Spotted Fever, chlamydia, community-acquired MRSA
• Mostly hepatic elimination
PANCE/PANRE Review Course
Tetracyclines
• AEs: photosensitivity, deposition in teeth and bones (no peds & pregnancy), GI, vestibular reactions (minocycline), hepatotoxicity
• Drug Interactions: chelation with divalent and trivalent cations, oral contraceptives, warfarin
PANCE/PANRE Review Course
Glycylcyclines (tigecycline-Tygacil)
• Parenteral
• MOA: protein synthesis inhibitor
• Spectrum: gram-positive (including MRSA), gram-negatives, anaerobes, atypicals
• Indications: alternative agentg
• AEs: GI, photosensitivity, tooth discoloration (no peds or pregnancy)
12
PANCE/PANRE Review Course
Aminoglycosides(gentamicin, tobramycin, amikacin)
• Parenteral
• MOA: protein synthesis inhibitors
• Spectrum: aerobic gram-positives and gram-negatives (P. aeruginosa)
• Concentration dependent efficacy and post antibiotic effect• Concentration dependent efficacy and post-antibiotic effect
• Indications: generally gram-negative infections in hospital
• Synergy with beta-lactams
• AEs: nephrotoxicity, ototoxicity, neuromuscular blockade (myasthenia gravis)
• Renally excreted
• Monitor serum concentrations
PANCE/PANRE Review Course
Sulfonamides
• MOA: inhibit folic acid synthesis
• Spectrum: gram-positive (Staphylococcus aureus, Streptococcus pneumoniae) and gram-negative (H. influenzae, Moraxella catarrhalis, E coli, Proteus) Pneumocystic jiroveci
• Indications: trimethoprim/sulfamethoxazole (TMP/SMX [Bactrim, Septra]): respiratory tract infections, UTIs, PCP, community-acquired MRSA
• AEs: GI, hypersensitivity (includes Stevens Johnson Syndrome), bone marrow suppression, photosensitivity
• DIs: oral contraceptives, warfarin, sulfonylureas
PANCE/PANRE Review Course
Metronidazole (Flagyl)Tinidazole (Tindamax)
• Oral/parenteral
• Spectrum: anaerobes (Bacteroides, C. difficile) and parasites (Trichomonas, Giardia, Entamoeba), H. pylori
I di ti GI i f ti l i l i f ti• Indications: GI infections, gynecological infections, trichomoniasis
• Hepatic elimination
• AEs: metallic taste, GI, CNS, dark urine
• Drug Interactions: warfarin
• Alcohol intolerance (flushing, tachycardia, N/V, hypotension, dyspnea)
13
PANCE/PANRE Review Course
Fidaxomicin (Dificid)
• Oral
• MOA: inhibits protein synthesis
• Spectrum: Clostridium difficile
• Not systemically absorbed
• AEs: nausea, vomitingAEs: nausea, vomiting
PANCE/PANRE Review Course
Clindamycin
• MOA: inhibit protein synthesis
• Spectrum: gram positive and anaerobes
• MRSA – community-acquired
• Hepatic elimination
• Alternative agent in penicillin allergic patientsAlternative agent in penicillin allergic patients
• AEs: GI – pseudomembranous colitis
PANCE/PANRE Review Course
Rifampin
• MOA: inhibits RNA synthesis
• Indications: TB, eradication of nasal carriage of H. flu, Meninogococcus, Staphylococcus, additional agent for resistant infections
• Hepatic elimination
• AEs: orange-red body fluids, hepatotoxicity, GI, flu-like symptoms
• Drug Interactions: induces cytochrome P450
14
PANCE/PANRE Review Course
Methicillin-Resistant Staphylococcus aureus (MRSA)
• Vancomycin
• Linezolid (Zyvox) and Tedizolid (Sivextro) - oral
• Dalfprostin/quinupristin (Synercid)
• Daptomycin (Cubicin)
• Lipoglycopeptides: telavancin (Vibativ), oritavancin (Orbactiv), dalbavancin (Dalvance)
• Others: tigecycline, ceftaroline
• Community: clindamycin, tetracycline , trimethoprim/sulfamethoxazole- oral
PANCE/PANRE Review Course
Vancomycin
• Inhibits cell wall synthesis – binds to peptidoglycan precursor and prevents cross-linking of peptidoglycan strands (different than beta-lactams)
• Parenteral: MRSA – drug of choice, also other staph and strep infections and Enterococcus faecalis
• Oral – not absorbed - C. difficile treatmentOral not absorbed C. difficile treatment• Renal excretion• AEs: red man’s syndrome, thrombophlebitis, nephrotoxicity,
ototoxicity• Monitor serum concentrations – trough concentrations –
10-20 mg/L
PANCE/PANRE Review Course
Oxazolidinones
• Linezolid (Zyvox) and Tedizolid (Sivextro)• Oral/Parenteral• Inhibit protein synthesis• MRSA, enterococci, streptococci• AEs: myelosuppression (monitor CBC), GI, headache,
thneuropathy• Drug interactions:
– Linezolid inhibits monoamine oxidase (MAO) – avoid tyramine (aged cheese, sausage, beer), selective seretonin reuptake inhibitors (SSRIs), pseudoephedrine, tricyclic antidepressants, bupropion, sumatriptin, beta2 agonists, sympathomimetics, tryptophan, ginseng, dopamine, dobutamine, sibutramine
15
PANCE/PANRE Review Course
Lipoglycopeptides• Telavancin (Vibativ), Oritavancin (Orbactiv), Dalbavancin
(Dalvance)
• All parenteral only
• Vancomycin derivatives
• Spectrum: MRSA, streptococci, enterococci
• Dalbavancin 2 doses one week apart• Dalbavancin – 2 doses one week apart
• Oritavancin – single dose
• AEs: nausea, vomiting, headache, diarrhea, infusion reactions– taste disturbances, QT prolongation, foamy urine, and
nephrotoxicity with telavancin
• DIs - CYP450 - oritavancin - warfarin (CYP2D6)
• Coagulation test interference: telavancin and oritavancin
PANCE/PANRE Review Course
Methicillin-Resistant Staphylococcus aureus (MRSA)
• Dalfprostin/quinupristin (Synercid) – IV
– AEs: arthralgias, rash, hyperbilirubinemia, N/V, headache
– Inhibits CYP450
• Daptomycin (Cubicin) – IV
– AEs: increased CPK (monitor weekly), GI, CNS
PANCE/PANRE Review Course
UTIs
• Nitrofurantoin
• Fosfomycin
• Methenamine
• All have some GI effects
• Generally recommended treatment for uncomplicated UTI is trimethoprim/sulfamethoxazole
16
PANCE/PANRE Review Course
Herpes Viruses
• acyclovir (Zovirax), famciclovir (Famvir), valacyclovir (Valtrex)• Herpes simplex (first episode, treatment/suppression of
recurrences, decrease transmission)• Herpes zoster – varicella (speed healing, decrease pain &
neuralgia)• Severe infectionacyclovir• Severe infectionacyclovir• AEs: GI, headache
PANCE/PANRE Review Course
Influenza• Zanamivir (Relenza – inhaled), oseltamivir (Tamiflu - oral),
peramivir (Rapivab - IV)
– Influenza A and B treatment (w/in 2 d) and prevention
– Influenza A resistance to oseltamivir
– Zanamivir – bronchospasm
– Oseltamivir – nausea vomiting HAOseltamivir nausea, vomiting, HA
– Peramivir – diarrhea
• Amantadine and rimantadine
– Influenza A treatment and prevention (due to resistance issues not currently recommended)
– AEs: GI, CNS (less with rimantadine)
PANCE/PANRE Review Course
Cytomegalovirus (CMV)
• Ganciclovir (Cytovene), valganciclovir (PO, Valcyte) – bone marrow suppression
• Foscarnet (Foscavir) –nephrotoxicity, electrolyte disorders, bone marrow suppression
• Cidofovir (Vistide) – nephrotoxicity, neutropenia
• Fomivirsen (Vitravene) – ocular toxicity
17
PANCE/PANRE Review Course
Hepatitis B
• Preferred Agents:
– Nucleos(t)ide analogues: (entecavir [Baraclude], tenofovir [Viread])
– Interferon, pegylated interferon
• Nonpreferred treatments: lamivudine, adefovir, telbivudine, emtricitabine
• All treatment decrease HBV DNA levels and have been associated with HBeAG loss/seroconversion, decreases in ALT, and improvements in liver histology
PANCE/PANRE Review Course
Hepatitis B
• Nucleos(t)ide analogues (oral)– Greater and faster decline in HBV DNA levels than with
interferon– Long-term treatment required– Resistance issues (low with tenofovir and entecavir)– Minimal side effects – HA, GI
• Interferon (SC)– 16 – 48 weeks treatment duration– AEs: many, including flu-like symptoms, bone marrow
suppression, and psychiatric symptoms
PANCE/PANRE Review Course
Hepatitis C – Initial Treatment - Directly acting antivirals
• Genotype 1a– Ledipasvir/Sofosobuvir (Harvoni)
– Ombitasvir/Paritaprevir/Ritonavir/ Dasabuvir (Viekira Pak) + Ribavirin
– Simeprevir (Olysio) + Sofosobuvir (Sovlaldi) +/- ribavirin
• Genotype 1b– Ledipasvir/Sofosobuvir (Harvoni)
– Simeprevir (Olysio) + Sofosobuvir (Sovaladi)
– Ombitasvir/Paritaprevir/Ritonavir/ Dasabuvir (Viekira Pak) +/-ribavirin
• Genotype 2– Sofosobuvir (Sovaldi) + ribavirin
• Genotype 3– Sofosobuvir (Sovaldi) + ribavirin
http://www.hcvguidelines.org
18
PANCE/PANRE Review Course
Hepatitis C – Adverse events• Sofosobuvir (Sovaldi): fatigue, headache, nausea
• Simeprevir (Olysio) + sofosobuvir (Sovaldi): fatigue, headache, nausea, insomnia, pruritus, rash, photosensitivity
• Ombitasvir/paritaprevir/ritonavir/ dasabuvir (Viekira Pak): skin reactions, insomnia, asthenia, irritability, fatigue, s eac o s, so a, as e a, ab y, a gue,pruritus, nausea, increased bilirubin and LFTs, anemia (contraindications due to drug interactions)
• Ledipasvir/sofosobuvir (Harvoni): fatigue, headache, nausea, diarrhea, insomnia
• Ribavirin: anemia, teratogen
• Multiple drug interactions (CYP450, acid suppressiondecreases absorption)
PANCE/PANRE Review Course
Antifungals
• Polyenes: amphotericin – wide spectrum• Azoles: ketoconazole (Nizoral), fluconazole (Diflucan),
itraconazole (Sporonax), voriconazole (Vfend), posaconazole (Noxafil) – spectrum varies from one agent to the other
• Terbinafine (Lamisil) dermatophyte infections• Terbinafine (Lamisil) – dermatophyte infections• Flucytosine – only as part of combination therapy• Echinocandins: caspofungin (Cancidas), micafungin
(Mycamine), anidulafungin (Eraxis) – candida and aspergillosis
PANCE/PANRE Review Course
Antifungals – Adverse Events
• Amphotericin: nephrotoxicity, electrolyte disorders, anemia, flu-like symptoms
• Azoles: hepatotoxicity, QT prolongation, ketoconazole-decreased cortisol & testosterone, voriconazole-vision
• Terbinafine: hepatotoxicityTerbinafine: hepatotoxicity• Echinocandins: histamine-mediated reactions,
hepatotoxicity, GI, HA, fever, phlebitis, hypokalemia, bone marrow suppression
• Griseofluvin: GI, HA, hepatotoxicity• Flucytosine: bone marrow suppression, GI, hepatitis
19
PANCE/PANRE Review Course
Antifungals – Important Drug Interactions
• Azoles inhibit cytochrome P450
• Ketoconazole & itraconazole require GI acidity for absorption
• Rifampin increases clearance of azoles
PANCE/PANRE Review Course
Bugs and Drugs
• Methicillin sensitive Staphylococcus aureus (MSSA): penicillinase-resistant penicillin (eg, nafcillin, dicloxacillin), first-generation cephalosporin
• MRSA serious: vancomycin
• MRSA outpatient: clindamycin, tetracycline, linezolid p y , y ,
• Streptococcus pyogenes: penicillin or amoxicillin, first generation cephalosporin
– penicillin allergic – clindamycin or macrolide
• Streptococcus pneumoniae – outpatient infections –penicillin V, amoxicillin, cephalosporins, macrolides
PANCE/PANRE Review Course
Bugs and Drugs
• Haemophilus influenzae and Moraxella catarrhalis: second or third generation cephalosporin, amoxicillin + clavulanic acid
• Pseudomonas aeruginosa –
– Oral: ciprofloxacin and levofloxacinp
– Intravenous: ticarcillin, piperacillin, ceftazidime, cefepime, aztreonam, aminoglycosides, carbapenems (except ertapenem), ceftolozane + tazobactam
20
PANCE/PANRE Review Course
Bugs and Drugs
• Neisseria gonorrhoeae: ceftriaxone + azithromycin or doxycycline
• Neisseria meningitis: ceftriaxone, cefotaxime
• Clostridium difficile: metronidazole, vancomycin, fidaxomicin
• Chlamydia: azithromycin and doxycycliney y y y
• Mycoplasma pneumoniae: macrolide or tetracycline
• Borrelia burgdorferia (Lyme): doxycycline, amoxicillin, cefuroxime axetil
• Treponema pallidum (Syphilis): penicillin G, benzathine penicillin
• Helicobacter pylori: proton pump inhibitor + clarithromycin + amoxicillin or metronidazole
PANCE/PANRE Review Course
Antibiotic Adverse Events Highlights
• Photosensitivity – SMP/TMX, tetracyclines, fluoroquinolones, tigecycline, hepatitis C treatments
• Rash – multiple agents (fluoroquinolones*)
• QT prolongation – macrolides, fluoroquinolones, telithromycin lipoglycopeptidestelithromycin, lipoglycopeptides
• Infusion reactions – vancomycin, lipoglycopeptides
• Nephrotoxicity – vancomycin, aminoglycocides, amphotericin, penicillins, tetracycline (outdated), foscarnet, cidofovir
• Hepatotoxicity – antifungals
• Ototoxicity – aminoglycosides, minocycline (vestibular), amphotericin
PANCE/PANRE Review Course
Adverse Events Highlights
• Seizures – penicillin, fluoroquinolones, carbapenems
• Mononucleosis – erythematous rash – amoxicillin
• Bone marrow suppression –sulfamethoxazole/trimethoprim, linezolid, ganciclovir, foscarnet interferon flucytosinefoscarnet, interferon, flucytosine
• Clostridium difficile infections – all (clindamycin*)
• GI – multiple agents (clavulanate*)
21
PANCE/PANRE Review Course
Adverse Events Highlights
• Taste disturbance – clarithromycin, metronidazole, tinidazole, telavancin
• Tendonitis – fluoroquinolones
• Orange-red fluids – rifampin
• Discolored teeth and bone deposits - tetracyclinesp y
• Contraindicated in pediatrics and pregnant women-tetracyclines, fluoroquinolones, tigecycline, telithromycin
• Contraindicated in neonates: sulfa agents
• Teratogen - ribavirin
PANCE/PANRE Review Course
Drug Interactions Highlights
• Macrolides, dalfopristin/quinupristin, telithromycin , azole antifungals – inhibit cytochrome P450
• Rifampin – induces cytochrome P450
• Fluoroquinolones and tetracyclines – chelated by divalent d t i l t tiand trivalent cations
• Linezolid – monoamine oxidase inhibitors
• Alcohol – disulfuram reaction (headache, tachycardia, flushing, GI) - metronidazole, cefotetan
• Hepatitis C and HIV treatments – multiple cytochrome P450 interactions
• Decrease in GI acidity decreases absorption of some azoles and some antivirals (hepatitis C and HIV)
PANCE/PANRE Review Course
Thank you!Thank you!